Bio & path
Reshma Kewalramani is the CEO and President of Vertex Pharmaceuticals (Boston), and one of the few physicians leading a top-tier U.S. biotech. Trained in internal medicine and nephrology, she spent more than a decade at Amgen in development leadership roles before joining Vertex in 2017 as Chief Medical Officer — and in April 2020 became CEO. Her career arc — clinician → drug-developer → CEO — gives her a uniquely patient-centric lens on portfolio strategy and regulatory decisions.
Recent advances
In January 2025, Vertex won FDA approval for suzetrigine (brand JOURNAVX, formerly VX-548), a first-in-class, non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain. The approval — supported by prior positive Phase 3 results — marked the first new analgesic class for acute pain in over two decades and signaled progress on the long-standing need for effective opioid alternatives. Business and medical trades alike flagged the milestone as one of the most consequential approvals of the year.
Beyond pain, Vertex continues to expand its cystic fibrosis leadership and to invest across gene-editing and renal programs, while also navigating the ordinary ups and downs of drug development (including 2025 pipeline volatility and investor scrutiny that Kewalramani addressed head-on, even purchasing stock on the open market after a selloff). The broader story is a company that has repeatedly delivered first-in-class medicines and is now leveraging its scientific engine to tackle larger markets — without losing sight of rigorous evidence and safety.
Why she matters to Movers & Shakers
Kewalramani embodies the “doctor-in-the-C-suite” who can translate patient need into portfolio bets and operational execution. Under her leadership, Vertex has shown that methodical, biology-first R&D can produce durable value — and that there’s room for big-impact innovation well beyond oncology. Recognition keeps following: 2025 business press included her among the year’s most powerful leaders in U.S. business, underscoring how a physician can shape markets, not just clinics.
The business & policy angle
Acute-pain management has been a policy flashpoint for years; a non-opioid, oral option with robust efficacy gives hospitals, ambulatory surgery centers, and payers a new lever to reduce opioid exposure while maintaining pain control. That has ramifications for formularies, quality metrics, and even workforce safety. Your piece can show how Vertex balanced clinical rigor and speed — and how a physician-CEO structured the narrative around patient-level benefit and system-level value.
Why now
The JOURNAVX launch gives you a timely hook, and Kewalramani’s continued visibility with investors and media makes the story relevant to both healthcare readers and broader business audiences. Pair the approval with a look at Vertex’s pipeline discipline to give your readers a crisp case study in physician-led biotech leadership.
